
Norethindrone
Where is Norethindrone used?Norethindrone is a man-made...
Niraparib is indicated as a maintenance treatment for the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. This is usually used in patients who are in complete or partial response to platinum-based chemotherapy. This medication is usually started within 8 weeks following the most recent platinum-containing regimen.
Theepithelial ovarian, fallopian tube, or primary peritoneal cancers are diseasesin which malignant cells form in the tissue covering the ovary or lining thefallopian tube. The epithelial ovarian, fallopian tube or primary peritonealcancers form in the same type of tissue and are treated the same way.Sometimes, these conditions are caused by inherited gene mutations. The genesin cells carry the hereditary information that is received from a person’sparents. Epithelial ovarian, fallopian tube or primary peritoneal cancers may notcause early signs or symptoms when signs and symptoms do appear, the cancer isoften advanced. Signs and symptoms may include:
Theovaries are a pair of organs in the female reproductive system. They are in thepelvis. Each ovary is about the size and shape of an almond. The ovaries makeeggs and female hormones.
Thefallopian tubes are a pair of long slender tubes one on each side of theuterus. Cancer sometimes begins at the end of the fallopian tube near the ovaryand spreads to the ovary.
Theperitoneum is the tissue that lines the abdominal wall and covers organs in theabdomen. Primary peritoneal cancer forms in the peritoneum.
Niraparibis in the class of PARP inhibitors. This drug is a white to off-white andnon-hygroscopic crystalline solid. This comes as a capsule that contains 159.4Niraparib and is equivalent to 100 mg free bases as the active ingredient. TheFood and Drug Administration (FDA) has already approved thisprescription.
How doesNiraparib work?
Niraparib is a poly ADP-ribose polymerase (PARP) enzyme inhibitor. It is highly selective for PARP1 and PARP2. PARP1 and PARP2 are involved in detecting DNA damage and promote repair. Inhibiting PARP1and PARP2 enzymatic activity results in DNA damage, apoptosis, and cell death. This medication induces cytotoxicity in tumor cell lines with or without BRCA1/2 deficiencies.
How touse Niraparib?
Thismedication is taken by mouth at bedtime to lessen the risk of nausea andvomiting. Each dose of this drug may be taken with or without food. Swallow themedicine as a whole with a full glass of water. Do not crush or dissolve thedrug. Do not change your dose or stop taking this unless your doctor tells youto do so. If you missed a dose, take your next dose at your usual scheduledtime. Do not take an extra dose to make up for a missed dose.
Thedosage is based on your medical condition and response to the treatment. Yourdoctor may start giving a lower dose with this medication and graduallyincrease it. If you vomit after taking Niraparib do not take another dose justcontinue your regular dosing schedule. Your doctor may reduce your dose orpermanently or temporarily stop your treatment if you experience certain sideeffects. Be sure to tell your doctor about how you feel during your treatmentwith Niraparib.
What arethe side effects of Niraparib?
Commonside effects:
Seek formedical emergency right away if you have a fever of 38 C or higher with chillsor any possible signs of infection. If you have any other side effects thatwon’t go away, let your doctor know at once.
Precautions